Locoregional Stomach Cancer
Gastric Pyloric Adenocarcinoma
Male, 39 years
Patient Internal ID: 266349119
ICD-10 code
C16.3 Malignant Neoplasm of Pyloric Antrum
Diagnosis (Incl. Metastases/Stage) and Year
February 2019
Gastric Pyloric Adenocarcinoma cT3NXM0 (pT3pN2M0 G3 (pLVI0)) stage III.
Previous Treatment
Surgery, Chemotherapy (FLOT scheme).
Prognosis and Survival Expectation
The prognosis remains poor, the median overall survival for Locoregional Gastric Cancer is about 43 months. The 5-year relative survival rates for Locoregional Stomach Cancer are 35%.
Treatment Provided
Autologous DCV (10 doses) and CIK (4 doses) over a period of 14 months. Additionally, the patient received Xenogeneic Preventive and Therapeutic Anti-Cancer Vaccine (PTAC) (10 vaccines).
Patient Survival/Condition and Year
Date of Review: 02/12/2023
The patient has survived for 47 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Surgery and Chemotherapy, has extended patient survival by an estimate of around 5 months so far. The patient has no signs of disease recurrence.
